TD Cowen lowered the firm’s price target on Evolent Health (EVH) to $14 from $36 and keeps a Buy rating on the shares. The firm said they believe management’s 2025 framework represents a true floor for expectations, particularly given the downside protections the company has embedded into 2/3 of its PS arrangements. Cowen believes this framework provides the company with conservative targets for which it can achieve and beat.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVH:
- Evolent Health price target lowered to $12 from $18 at JMP Securities
- Evolent Health price target lowered to $16 from $23 at Canaccord
- Evolent Health price target lowered to $15 from $20 at Truist
- Evolent Health price target lowered to $20 from $29 at BTIG
- Evolent Health price target lowered to $12 from $16 at Stephens